GILD
Gilead Sciences, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website gilead.com
- Employees(FY) 17000
- ISIN US3755581036
Performance
-0.75%
1W
-10.14%
1M
-14.95%
3M
-18.68%
6M
-19.2%
YTD
-15.25%
1Y
Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc., and Tentarix Biotherapeutics Inc., as well as a partnership with Assembly Biosciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was incorporated in 1987 and is headquartered in Foster City, California.
Investment Analysis Report: Gilead Sciences Inc. (GILD)
Overview:
Gilead Sciences Inc. (GILD) operates in the Health Technology sector, specifically in the Biotechnology industry. The company has a market capitalization of $91.65 billion. In this report, we will conduct a comprehensive analysis of GILD's financial health, valuation, earnings and...
Technical Analysis of GILD 2024-05-03
Overview:
In analyzing the technical indicators for GILD over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for potential invest...
Recent News & Updates
- 2024-05-04 07:38
23 Most Profitable Stocks of the Last 12 Months(Insider Monkey)
- 2024-05-04 02:00
- 2024-05-03 20:11
Analyst Report: Gilead Sciences, Inc.(Morningstar Research)
- 2024-05-03 19:38
23 Most Profitable Stocks of the Last 12 Months(Insidermonkey)
- 2024-05-03 14:00
- 2024-05-03 05:08
- 2024-05-02 11:29
- 2024-05-02 10:02
- 2024-05-02 02:38
- 2024-05-01 10:53
- 2024-05-01 10:19
- 2024-05-01 04:05
- 2024-05-01 00:01
- 2024-04-30 20:25
- 2024-04-30 16:05
Gilead Sciences to Present at Upcoming Investor Conferences(Business Wire)
- 2024-04-30 12:01
- 2024-04-29 21:00
- 2024-04-29 09:00
- 2024-04-29 08:18
- 2024-04-29 06:01
Gilead expands FDA label for Biktarvy with Phase I pregnant HIV patient data(Clinical Trials Arena)
- 2024-04-28 05:50
American Politicians are Selling These 10 Stocks(Insidermonkey)
- 2024-04-27 10:29
- 2024-04-26 23:44
3 Dividend Stocks to Buy at a 52-Week Low in April(Investorplace)
- 2024-04-26 22:24
- 2024-04-26 20:00
- 2024-04-26 16:31
Analyst Report: Gilead Sciences, Inc.(Morningstar Research)
- 2024-04-26 12:17
Gilead Gives Up Big Gains As Covid Drug Drives Its Beat — Again(Investor's Business Daily)
- 2024-04-26 10:45
- 2024-04-26 10:24
- 2024-04-26 10:09
Page 1 of 10
previousnext